131i-sibrotuzumab
mAbexperimentalADC
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2000 (NCT02209727)
Timeline
2000s
- Jan 1, 2000
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Fibroblast activation protein alphaRadiodepletion
FAP radiodepletion
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 131-iodine
Oral
No
Parenteral
No
Topical
No
Also known as
- 131i-sibrotuzumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02209727 | Phase 1 | Dec 1, 2000 | Boehringer Ingelheim |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 1 | 1 | 1 | 2000 |
1 organizations
Page 1 / 1